Cold Email Sequence for Medtech: 5-Touch Framework
Medtech buyers are trained to distrust claims. Clinicians want published evidence, procurement wants risk taken off the table, and administrators have watched a hundred vendors promise workflow miracles that turned into support tickets. A cold email sequence for medtech has to work inside that skepticism rather than around it.
We build and run outbound systems for medtech and health tech companies, from device manufacturers to clinical software to services selling into hospitals and private practices. This guide is the 5-touch framework we use: the spacing, five complete scripts with subject lines, personalization rules by role, and the compliance guardrails that keep a program clean.
Why medtech outbound is different
Four realities separate medtech from a standard B2B motion.
- Sales cycles are long and committee-driven. A hospital purchase moves through value analysis committees, capital budget calendars, and often a GPO contract. A reply is the start of a months-long process, so the sequence's job is opening the right conversation, not closing anything.
- The culture runs on evidence. Your buyers read clinical literature for a living or work next to people who do. Vague superlatives cost credibility, while a specific, checkable number builds it.
- Buyers are compliance-aware. They notice when vendor language overreaches on claims, and they judge the sender by it. Every sentence should survive a skeptical read.
- Hospital procurement and private practice are different markets. The hospital buyer navigates committees and fiscal-year windows; the practice owner or ASC administrator can decide in weeks and cares about cash flow. Segment your lists and run separate sequences, because copy that fits one reads wrong to the other.
Email is one channel inside this motion; our guide to outbound sales for medtech covers the full picture.
The 5-touch framework at a glance
Five touches over 24 days, slower than the 14-18 day cadences common in SaaS. The gaps are deliberate: medtech buyers punish crowding.
| Touch | Day | Angle | Thread |
|---|---|---|---|
| 1 | Day 1 | Situation-trigger opener | New thread |
| 2 | Day 4 | Value-add with proof or a resource | Reply to touch 1 |
| 3 | Day 9 | New angle: workflow or budget cycle | New thread |
| 4 | Day 16 | Short case-study bump | Reply to touch 3 |
| 5 | Day 24 | Clean breakup | New thread |
The thread strategy matters as much as the spacing. Touches 2 and 4 reply to the email before them, keeping context one scroll away. Touches 3 and 5 open fresh threads, because a new angle deserves a new subject line. The reasoning behind multi-touch spacing in general is in our cold email sequence structure guide; everything below is the medtech-specific version.
One operational rule sits above all five touches: a reply of any kind stops the sequence the same day. Clinical and procurement circles are small, and a follow-up that ignores an answer the buyer already sent travels between facilities.
Touch 1 (Day 1): The situation-trigger opener
The first email earns everything after it, so anchor it to something true about the buyer's world right now.
Subject line options:
- question about {{facility_name}}
- {{first_name}}, noticed the {{trigger}}
- quick question on {{department}}
Email copy:
``` Hi {{first_name}},
Saw that {{company}} {{trigger: opened the new ASC in Plano, cleared the 510(k) on the G2 line, added two ORs at the main campus}}.
When that happens, {{role plural: perioperative directors, practice administrators}} usually inherit {{specific problem: device tracking across sites, case scheduling backlogs, a heavier prior auth load}}.
We help {{peer descriptor: surgical device teams, multi-site imaging groups}} {{plain outcome}}. {{Proof point: a named client or a number they can check}}.
Worth 20 minutes to see if it applies at {{company}}?
{{sender_name}} {{title}}, {{sender_company}} ```
Why it works: The trigger proves a human looked before writing. The problem belongs to the role and is stated without drama, and the ask is a bounded 20 minutes, respectful of a calendar that runs in 15-minute blocks.
Touch 2 (Day 4): The value-add
Touch 2 gives before it asks again. It replies in the same thread, so the original context sits right below.
Subject line: none needed, this one replies to touch 1.
Email copy:
``` {{first_name}}, one thing that might be useful whether or not we talk.
We put together {{resource: a benchmark of device evaluation timelines across 40 facilities, a checklist for value analysis submissions}}. The part most {{role plural}} flag is {{one specific takeaway}}.
Happy to send it over, no call attached.
And if {{problem}} is on the list this quarter, I will make 20 minutes worth your time.
{{sender_name}} ```
Why it works: A resource with one named takeaway signals substance without demanding trust. "No call attached" lowers the guard, and a prospect who requests it has started a conversation you can build on.
Touch 3 (Day 9): The budget or workflow angle
If the pain angle did not land, timing might. Touch 3 opens a new thread with a different lens: capital budget cycles for hospital targets, daily workflow for practices.
Subject line options:
- {{company}} capital planning
- {{first_name}}, workflow question
Email copy:
``` Hi {{first_name}},
Setting my earlier note aside, different question.
Most {{facility type: health systems, ortho practices, imaging groups}} we work with are either building next year's capital requests right now or stretching the current {{equipment or process}} one more cycle.
If {{problem}} is anywhere on that list, the decision usually comes down to {{concrete trade-off: service contract costs against replacement, staff hours per case, denial rates on claims}}.
We built a simple model for that math. Want me to run it for {{company}}?
{{sender_name}} ```
Why it works: The budget angle catches buyers whose pain is real but unfunded, which in medtech is most of them. The offer is a concrete piece of work, not another request for attention.
Touch 4 (Day 16): The case-study bump
Short, specific, and sitting in the thread from touch 3.
Subject line: none, this replies to touch 3.
Email copy:
``` {{first_name}}, an example instead of another pitch.
{{Peer: a 12-OR hospital in the Midwest, a 3-site imaging group}} was dealing with the same {{problem}}. {{What changed, one plain sentence}}. {{The result, with one number they could verify}}.
The full write-up is two pages, and it names the workflow changes that mattered. Want a copy?
{{sender_name}} ```
Why it works: Medtech decisions move on peer evidence, and this is peer evidence in miniature. A two-page ask is small enough to accept between cases, and every yes is a warm conversation.
Touch 5 (Day 24): The clean breakup
The last email closes the loop like a professional, not a salesperson chasing quota.
Subject line options:
- closing the loop
- {{first_name}}, last note from me
Email copy:
``` Hi {{first_name}},
I will stop here, since {{problem}} clearly is not near the top of the list right now.
Two things we consistently see work in {{segment}}, in case they help later: {{insight one, one sentence}}. {{insight two, one sentence}}.
If the picture changes, my line is open. Good luck with {{something real: the new site, the launch, survey season}}.
{{sender_name}} {{title}}, {{sender_company}} ```
Why it works: A decisive ending is easier to answer than an open loop, so breakups often draw replies the middle touches missed. Leaving two real insights behind means the last impression is value, not pressure.
Personalization that moves replies
Role determines the message, because the same product means three different things inside one facility.
- Clinical buyers such as medical directors, department chiefs, and clinical engineering care about workflow and evidence. Show what changes in their day and what data backs it.
- Procurement and supply chain care about total cost, contract terms, vendor risk, and GPO alignment. Elegance means nothing here; predictability means everything.
- Administrators and practice owners care about throughput, staffing hours, and revenue cycle impact. Frame outcomes in schedules and dollars.
Trigger events are the other half. New facility or expansion announcements, a device launch, a clearance or regulatory milestone, and leadership changes all create windows when your problem is already being discussed internally. Hold yourself to two verifiable facts per prospect before a contact enters the sequence. For a line-by-line breakdown of a single email, see our cold email template for medtech.
Compliance notes that keep the program clean
Three rules cover most of the risk:
- No PHI, ever. Cold outreach should never reference patient information in any form. If a data vendor offers patient-level anything, walk away.
- Match claims language to your regulatory status. Cleared is not approved, and an indication is not a promise. Check every product statement against what is on file with the FDA before it appears in an email, and keep efficacy claims out of cold email entirely: describe the operational problem, cite checkable proof, and save product claims for the meeting.
- Cover the CAN-SPAM basics. Accurate sender identity, truthful subject lines, a physical mailing address, and a working unsubscribe honored promptly.
What results to expect
Run well, a medtech sequence lands in the same bands we see across cold outbound: a 1-5% reply rate, with 15-50% of those replies positive. Keep hard bounces under 2%; anything higher means the list needs re-verification before the next send.
We do not track opens on any program we run. The tracking pixel hurts deliverability, privacy features made the number unreliable, and every decision worth making shows up in replies anyway. Judge subject lines by the replies they produce; our guide to cold email subject lines for medtech digs into what holds up.
Expect segments to behave differently. Hospital-heavy lists reply slowly, and conversations often surface weeks after touch 5. Private practice and ASC segments move faster and book sooner. Both patterns are normal, and the sequence's job is to start conversations the calendar can catch.
Medtech buyers do not reply to enthusiasm. They reply to specifics: their facility, their workflow, a number they can check. Write every email like the reader will fact-check it, because the good ones will.
Ready to book meetings with medtech buyers?
The sequence is the visible part; underneath it sit list building, verification, sending infrastructure, and reply handling. We build and run that whole machine for medtech companies, with a performance guarantee behind it.
Frequently Asked Questions
A strong positive reply rate for B2B cold email is 1.5–3%. Top-performing campaigns with tight targeting and personalized copy can hit 4–5%. If you're below 1%, it usually signals a deliverability or messaging problem — not a volume problem.
The safe range is 30–50 emails per inbox per day for warmed inboxes. That's why outbound systems use multiple inboxes (we use 80) — to reach 40,000+ monthly sends while keeping each inbox well within safe limits. Sending more than 50/day from a single inbox risks spam folder placement.
Yes. The CAN-SPAM Act permits unsolicited commercial email as long as you include a physical address, an unsubscribe mechanism, accurate headers, and non-deceptive subject lines. Unlike GDPR in Europe, the US does not require prior opt-in consent for B2B cold outreach.
Domain warm-up typically takes 2–3 weeks. During this period, sending volume gradually increases while the email warm-up tool generates positive engagement signals (opens, replies) to build sender reputation. Skipping or rushing warm-up is the most common cause of deliverability problems.
Cold email is targeted, relevant outreach to a specific person based on their role, industry, or company — with a clear business reason. Spam is untargeted mass messaging with no personalization or relevance. The distinction matters legally (CAN-SPAM compliance) and practically (deliverability depends on relevance signals).
Dimitar Petkov
Co-Founder of LeadHaste. Builds outbound systems that compound. 4x founder, Smartlead Certified Partner, Clay Solutions Partner.
